팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2024-03-04 큐리언트 기업설명회 IR 자료 공지
      2024-02-27 연결재무제표 기준 영업(잠정)실적(공정공시)
      2024-02-22 큐리언트 기업설명회 개최 공지
  • Press Release

      2024-1-26 큐리언트, 獨 대학 연구소 공동연구 헤르페스 바이러스 치료제 논문 ...
      2024-01-04 큐리언트, CDK7 저해제 ‘Q901’ “美 특허등록”
      2023-12-12 큐리언트, JPM헬스케어 콘퍼런스에서 기술이전 논의
      2023-12-05 큐리언트, 텔라세벡 허가 임상 개시 확정…1300억 확보 성큼
      2023-11-27 “큐리언트, 후보물질 가능성을 고려한 꾸준한 연구개발이 경쟁력”
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file